EPCAM and digestive system neoplasm: Next, the first-in-human, open-label, multi-centers trial (NCT05028933) in patients with EpCAM- positive relapsed/ refractory gastrointestinal (GI) tumors was designed to examine the safety, efficacy and cytokinetic profile of IMC001, an EpCAM- specific CAR-T cell based immunotherapy.